

Docket No. OON-0930  
Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane  
Rm 1061  
Rockville, Md 20852

To Whom It May Concern:

I would very much like to participate in either one or both of the expert working groups involving the development of biomarkers for drug-induced cardiac tissue injury or drug induced vasculitis. I have worked in the histopathologic interpretation of these lesions for industry and government for 22 years and in the last 3 years, have begun investigations into the use of blood gene expression as a marker for target organ toxicity with particular interests in the heart and cardiovascular system.

#### Biographical Summary

H.Roger Brown, M.S., D.V.M., D.A.C.V.P.  
Associate Director of Pathology  
GlaxoWellcome

B.A. Biology, Vanderbilt University, 1971  
M.S. Toxicology, Utah State University, 1974  
D.V.M., Auburn University, 1978  
Board Certification, American College of Veterinary Pathology, 1984  
Pathologist, Hazleton Laboratories, 1978-1985  
Pathologist, Experimental Pathology Laboratories, NTP reviewer, PWG participant 1985-1991  
Assoc. Dir. Pathology, Glaxowellcome, 1991-present

Vascular/cardiovascular interests and publications.

1978-1995

Histopathologic evaluation of a number of proprietary compounds with cardiovascular endpoints including beta blockers, catecholamines, phosphodiesterase inhibitors and calcium channel blockers, phospholipase A2 inhibitors and sodium ionophores.

1995-present

Team member of nuclear receptor target development-particularly, Troglitazone and selective PPAR-gamma agonists. Early pathologic investigations into issues of cardiac hypertrophy, edema and vascular changes.

1997-present

Began gene expression investigations into "good"(exercise induced) and "bad" (renovascular hypertension) cardiac hypertrophy. Adriamycin timecourse study with cardiac gene expression. Continuing investigations into correlations of blood gene expression and heart gene expression in PPAR gamma and Adriamycin treated animals.

Relevant Publications:

1. A TIME-COURSE STUDY OF GENE EXPRESSION PATTERNS AND PATHOLOGY IN THE HEARTS OF RATS TREATED WITH DOXORUBICIN HYDROCHLORIDE

H.R. Brown<sup>1</sup>, G. Benavides<sup>1</sup>, K. Hyder<sup>2</sup>, H. Ni<sup>1</sup>, L. Yoon<sup>1</sup>, G. Gardner<sup>1</sup>, B. Gaskill<sup>1</sup>, L. Brown<sup>1</sup>, L. Watkins<sup>1</sup>, K.T. Morgan<sup>1</sup>. <sup>1</sup> *GlaxoWellcome, Inc.: Research Triangle Park, NC*; <sup>2</sup> *Clontech Laboratories: Palo Alto, CA*

Poster, Society of Toxicology, Annual Meeting 2000, Philadelphia, Pa.

2. Exercise induced cardiac gene expression; a time course study. H.R. Brown, T. Mansfield, Yoon L. . <sup>1</sup> *GlaxoWellcome, Inc.: Research Triangle Park, NC.* ; <sup>2</sup> *Curagen Corporation, New Haven, Ct* Manuscript in preparation.

3. Correlation of Simultaneous Gene Expression in the Blood and Heart with Known Mechanisms of Doxorubicin-Induced Cardiomyopathy in the Rat. H.R. Brown<sup>1</sup>, H. Ni<sup>1</sup>, G. Benavides<sup>1</sup>, J. Giridhar, L. Yoon<sup>1</sup>, G. Gardner<sup>1</sup>, R. Tyler, K.T. Morgan<sup>1</sup>. <sup>1</sup> *GlaxoWellcome, Inc.: Research Triangle Park, NC.* Manuscript in preparation.

The publications and work above are included as evidence of interest in the focused subjects of cardiovascular and vascular endpoints. A complete list of publications can be obtained upon request.